AngioDynamics, Inc. reaffirms earning guidance for fiscal year 2024. The Company continues to expect its fiscal year 2024 net sales to be in the range of $328 to $333 million and gross margin to be approximately 50% to 52%. For comparison, pro forma revenue, gross margin, and adjusted loss per share for FY23 when excluding the assets divested to Merit Medical were $306.3 million, 50.5%, and $0.43, respectively.